No Data
No Data
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $17
Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position
Sector Update: Health Care Stocks Mixed Premarket Friday
12 Health Care Stocks Moving In Friday's Pre-Market Session